Neurocrine Biosciences (NBIX) Gross Profit Growth (3y) (2020 - 2026)
Neurocrine Biosciences (NBIX) Gross Profit Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | 6.23% |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | 3.42% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -0.01% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 8.70% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -3.26% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 28.48% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.60% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -10.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.48% |
| Mar 31, 2026 | 24.80% |
| Dec 31, 2025 | 24.91% |
| Sep 30, 2025 | 26.94% |
| Jun 30, 2025 | 254.33% |
| Mar 31, 2025 | 22.56% |
| Dec 31, 2024 | 26.17% |
| Sep 30, 2024 | 28.15% |
| Jun 30, 2024 | 26.68% |
| Mar 31, 2024 | 29.52% |
| Dec 31, 2023 | 27.41% |
| Sep 30, 2023 | 23.99% |
| Jun 30, 2023 | 13.72% |
| Mar 31, 2023 | 20.57% |
| Dec 31, 2022 | 18.72% |
| Sep 30, 2022 | 20.19% |
| Jun 30, 2022 | -56.28% |
| Mar 31, 2022 | 30.62% |
| Dec 31, 2021 | 33.32% |
| Sep 30, 2021 | 24.78% |